-
Why Galectin Therapeutics Just Lost Nearly Half Its Market Cap
Wednesday, September 28, 2016 - 10:59am | 352Shares of Galectin Therapeutics Inc (NASDAQ: GALT), a clinical-stage biopharmaceutical company that creates therapies for fibrotic disease and cancer, tumbled nearly 50 percent on Wednesday after the company said that a Phase 2a study called NASH-FX involving its GR-MD-02 therapy failed its...